Dr. Xinyu Wang | Decision Sciences | Best Researcher Award
Head of Health Ecomonics and Value Assessment sanofi Japan
Xinyu Wang is a distinguished expert in health economics and market access, currently leading the Health Economic and Value Assessment (HEVA) team at Sanofi Japan. With extensive experience across global pharmaceutical companies, he has made significant contributions in health technology assessment (HTA), pricing strategies, and real-world evidence generation. His work spans multiple therapeutic areas, including oncology, immunology, and neuroscience.
Profile
Education π
- Emory University, USA (2014 β 2016) β MBA, Goizueta Business School; Focus on health economics at Rollins School of Public Health
- University of Tokushima, Japan (2002 β 2007) β PhD in Pharmaceutical Science and Drug Delivery System (Recipient of Rotary International Scholarship)
- Shenyang Pharmaceutical University, China (1994 β 1999) β BS in Pharmaceutical Science (Japanese Special Course, passed JLPT highest level)
- Additional Training: Health economic courses at York University, Oxford University, Keio University, and YHEC.
Professional Experience π
- Sanofi Japan (Oct 2023 β Present) β Head of HEVA, leading a team of experts in economic assessments across vaccines, immunology, and oncology.
- Otsuka Pharmaceutical Co., Ltd. (Japan, 2016 β 2023) β Held multiple managerial roles in HTA, early pipeline market access, and pricing strategies, significantly influencing drug reimbursement strategies in Japan and Asia.
- Otsuka Pharmaceutical Europe Ltd. (UK, 2017 β 2021) β Led HTA submissions in Europe, developed cost-effectiveness models, and collaborated on real-world evidence studies.
- Otsuka Pharmaceutical Japan (2007 β 2014) β Senior researcher in formulation development, innovating drug delivery solutions for CNS disorders.
Research Interests π
Xinyu Wang specializes in:
- Health technology assessment (HTA) & health economic outcome research (HEOR)
- Cost-effectiveness modeling & real-world evidence generation
- Pricing strategies and market access for pharmaceuticals
- Patient-reported outcomes and quality-of-life research
- Global health policy impact and value-based healthcare strategies
Awards & Recognitions π
- Rotary International Scholarship (PhD program)
- Recognition for leadership in HTA and pricing at Otsuka Pharmaceuticals
- Multiple publications in top-tier journals highlighting contributions to health economics and patient outcomes research
Publications Top Notes: π
Haemoglobin Requirements of Clinical Trials Involving Anaemia in Chronic Kidney Disease β ASN 2020
Evaluating the Correlation between Monthly Migraine Days and Quality-of-Life β ISPOR Europe 2021
Modelling Monthly Migraine Day Distribution: A Case Study of Fremanezumab β ISPOR 2022
Modeling Monthly Migraine-Day Distributions Using Longitudinal Regression Models and Linking Quality of Life β Pharmacoeconomics, 2023
Cost-Effectiveness of Fremanezumab in Episodic and Chronic Migraine Patients β Pharmacoeconomics, 2024